St. Jude Medical (STJ)'s Durata Defibrillator "Immune" to Riata Flaws?
6/19/2013 8:06:33 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
St. Jude Medical's Durata implantable cardiac defibrillator leads should be "relatively immune" to the problems that led to a recall for the medical device company's Riata ICD leads, according to a cardiologist who helped bring the Riata problems to light. St. Jude Medical (NYSE:STJ) pulled its Riata implantable cardiac defibrillator leads in 2010 after mounting evidence suggested that the Riata leads were prone to abrading through their insulation. The move cast a pall over over St. Jude's newer ICD lead offerings, the Riata ST Optim and Durata leads.
Help employers find you! Check out all the jobs and post your resume.
comments powered by